| News for nuclear medicine and molecular imaging professionals |  |
| |
|
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple
internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher.
The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may
be directed to SmartBrief at snmmi@smartbrief.com.
|
- Only a few can access Amyvid PET scans
The FDA in April approved Amyvid, a PET imaging agent for Alzheimer's disease, but only a few people are getting the scans because the federal government and private insurers are not covering it. In the U.S., only about 300 practices or hospitals are offering the scans or are planning to in the near future, said Morry Smulevitz of Amyvid maker Lilly Bio-Medicines. CMS said it is reviewing potential coverage for the scans. The process could take a year, Smulevitz said. The Columbus Dispatch (Ohio)
(11/5)
|
|
 | The MEDRAD™ Intego™ is making personalized PET practical.
Clinicians are able to set weight-based dosing formulas to determine and administer a personalized minimum acceptable dose for each unique patient. Precise delivery and dose-on-demand capabilities enable lower patient dosing, leading to better patient care. To learn more, click here. |
|
|
| Clinical News & Research
|  |  |
|
- Study: Anti-TNF-alpha therapy aids patients with RA
Patients with rheumatoid arthritis manifest a subclinical vasculitis that may be linked to a higher risk of cardiovascular disease, and using anti-tumor necrosis factor alpha therapy may lessen this risk, researchers write in an editorial in Circulation. The researchers used F-FDG-PET/CT to determine vascular inflammation in patients. "Our data suggest that vascular inflammation could underpin the mechanism of increased CVD in RA, and also demonstrates that PET/CT scanning could be a useful tool for CVD risk stratification and for monitoring risk reduction of anti-inflammatory therapies in patients with chronic inflammatory diseases," according to the team. News-Medical.Net/medwireNews
(11/5)
| Industry Report
| | |
|
- Novelos gets funding for LIGHT facility
Novelos Therapeutics said it has secured $2 million from a Russian investor, an affiliate of Renova Group. The company will use the money to establish a production facility for its molecular cancer imaging agent I-124-CLR1404, also called LIGHT. The facility is set to be finished in one year. Wisconsin State Journal (Madison)
(11/5)
| News from the Field
| | |
|
- Group gives tips on how to improve breast density notification
The American Society of Breast Disease has released a statement with recommendations on how physicians can improve breast density notification for women. The recommendations include communicating the information in a way that women can comprehend and practicing shared decision-making. "If women know their lifetime risk ... and whether or not their breasts are dense, they will be better equipped to understand the recommendations their physicians make -- and make more informed screening decisions," the group said. AuntMinnie.com (free registration)
(11/5)
| International Developments
| | |
|
| Health Policy
| | |
|
| Advancing Health Care
| | |
|
- Group injects Alzheimer's funding into the political discourse
The Alzheimer's Association is mobilizing volunteers to attend political campaign events to get the candidates to talk about funding for Alzheimer's disease research. "We can either keep ignoring it with no treatment and no cure, and the majority of those costs will be paid by Medicaid and Medicare, or we can start funding research to find a cure," volunteer April Holden said. Roll Call (free content)
(11/1)
| From SNMMI
| | |
|
| SmartQuote
| | |
|
 | It's impossible to move, to live, to operate at any level without leaving traces, bits, seemingly meaningless fragments of personal information."
--William Gibson,
American-Canadian author
|
| |
| |
|
Read more at
SmartBrief.com |
|
|
|
| |
| |
| | Recent
SNMMI SmartBrief Issues:
- Monday, November 05, 2012
- Friday, November 02, 2012
- Thursday, November 01, 2012
- Wednesday, October 31, 2012
- Tuesday, October 30, 2012
| | | Lead Editor:
Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | |
| |
|
| © 1999-2012 SmartBrief, Inc.®
Legal Information |
|
